Avid Bioservices Inc (CDMO): They are not specific in the way they wr...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	62
Posts	1712
Boards Moderated	0
Alias Born	08/08/2005

sunstar

Re: nuke661 post# 104769

Sunday, 12/16/2012 8:38:10 PM

Sunday, December 16, 2012 8:38:10 PM

They are not specific in the way they write about the "survival". I’m sure that the idea is that they’re referring to MOS. The trial is supposed to still be under wraps. So they write a general statement which is maybe ballpark:

"Investors are likely to view a survival benefit of 8 months for Abraxane/gemcitabine compared to 6 months for gemcitabine alone as a very positive result."

They are making a subtle suggestion to their readers that they would be smart to buy that CELG stock now. But, just maybe somebody’s setting up a big short on CELG news. And, Motfool suggests that Abraxane could threaten PPHM.

The headline includes the words: “What to Watch”. Magicians like you to watch one hand while the action’s in the other. Maybe someone wants investors to buy that play while somebody else trickle accumulates PPHM. Naw, it couldn’t be!

JMO

sunstar